Synergistic antibacterial and anti-biofilm activities of resveratrol and polymyxin B against multidrug-resistant Pseudomonas aeruginosa

Bacterial infection caused by multidrug-resistant Pseudomonas aeruginosa has become a challenge in clinical practice. Polymyxins are used as the last resort agent for otherwise untreatable Gram-negative bacteria, including multidrug-resistant P.aeruginosa . However, pharmacodynamic (PD) and pharmaco...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antibiotics 2022-10, Vol.75 (10), p.567-575
Main Authors: Qi, Lin, Liang, Rongxin, Duan, Jingjing, Song, Songze, Pan, Yunjun, Liu, Hui, Zhu, Mingan, Li, Lian
Format: Article
Language:English
Subjects:
101/58
38/23
45/29
631/326/1320
631/326/22/1434
Antibacterial activity
Bacteria
Bacterial diseases
Bacterial infections
Bacteriology
Biofilms
Biomedical and Life Sciences
Bioorganic Chemistry
Drug resistance
Gram-negative bacteria
Life Sciences
Medicinal Chemistry
Microbiology
Multidrug resistance
Multidrug resistant organisms
Organic Chemistry
Pharmacodynamics
Pharmacokinetics
Pharmacology
Plasma levels
Polymyxin B
Polymyxins
Pseudomonas aeruginosa
Resveratrol
Synergistic effect
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bacterial infection caused by multidrug-resistant Pseudomonas aeruginosa has become a challenge in clinical practice. Polymyxins are used as the last resort agent for otherwise untreatable Gram-negative bacteria, including multidrug-resistant P.aeruginosa . However, pharmacodynamic (PD) and pharmacokinetic (PK) data on polymyxins suggest that polymyxin monotherapy is unlikely to generate reliably efficacious plasma concentrations. Also, polymyxin resistance has been frequently reported, especially among multidrug-resistant P.aeruginosa , which further limits its clinical use. A strategy for improving the antibacterial activity of polymyxins and preventing the development of polymyxin resistance is to use polymyxins in combination with other agents. In this study, we have demonstrated that resveratrol, a well tolerated compound, has synergistic effects when tested in vitro with polymyxin B on antibacterial and anti-biofilm activities. However, its’ systemic use is limited as the required high plasma levels of resveratrol are not achievable. This suggests that it could be a partner for the combination therapy of polymyxin B in the treatment of topical bacterial infection caused by MDR P.aeruginosa .
ISSN:0021-8820
1881-1469
DOI:10.1038/s41429-022-00555-1